Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Registration Number
- NCT06877676
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this pre-approval access program is to provide access to TAR-200 prior to its marketing authorization for the treatment of participant(s) with high-risk non-muscle invasive bladder cancer (HR-NMIBC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
NCT06877676 TAR-200 mechanism of action high-risk non-muscle invasive bladder cancer Janssen
TAR-200 comparative efficacy BCG immunotherapy HR-NMIBC clinical outcomes Janssen
Biomarkers TAR-200 patient selection HR-NMIBC FGFR3 TP53 response prediction Janssen
Adverse events safety profile TAR-200 HR-NMIBC management strategies Janssen pre-approval
TAR-200 combination therapies HR-NMIBC competitor drugs Janssen expanded access